– SWITZERLAND, Geneva – EBAMed SA, developer of medical technologies to transform the treatment of cardiac arrhythmias, today announced the appointment of experienced specialist Marina Izzo as CEO, succeeding to co-founder, Adriano Garonna who has transitioned to CTO and remains on the Board of Directors.
Mrs. Izzo will set the vision for EBAMed’s technology and lead the effort for the next financing round, planned for 2022.
“Marina has strong experience in leading medical device businesses and developing the market for groundbreaking cardiovascular technologies in Europe, North America and China,” said Board Chairman, Giovanni Leo. “Her experience will be invaluable as we realize our mission to shift the paradigm in electrophysiology from catheter-based ablation therapies to non-invasive EP procedures.”
About Marina Izzo
Mrs. Izzo served as CEO for Cardionovum, an innovative developer of drug-coated balloon technology. Before that, she was Senior Director of Sales and Marketing at Symetis SA, where she established the company as a key competitor in the transcatheter aortic valve implantation market. She has held several leadership roles with Medtronic in Europe and with St. Jude Medical, including Marketing Director for the EMEA Atrial Fibrillation (AF) business.
“Many patients fail or cannot undergo conventional invasive therapies such as ablation,” said Marina. Izzo. “I am very excited to continue exploring the potential of radiation oncology therapies in cardiac medicine and to realize EBAMed’s mission to change the lives of patients living with cardiac arrhythmias”.
Mrs. Izzo is a graduate of the Bocconi University of Milan.
EBAMed is an early-stage, private medical device company. EBAMed is developing a cardiac ultrasound product to improve radio ablation for Ventricular Tachycardia, a growing clinical need in the face of the prevalence of heart disease, and aging populations.
For more information, visit https://eba-med.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.